Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 29, 2024 16:05 ET | Source: ProKidney

ProKidney to Participate in Jefferies Biotech on the Bay Summit

WINSTON-SALEM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
November 30, 2023 06:05 ET | Source: ProKidney

ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer

WINSTON-SALEM, N.C., Nov. 30, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
November 21, 2023 06:05 ET | Source: ProKidney

ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference

WINSTON-SALEM, N.C, Nov. 21, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving...
November 14, 2023 06:05 ET | Source: ProKidney

ProKidney Reports Third Quarter Financial Results

WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
November 13, 2023 17:02 ET | Source: ProKidney

ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients Focusing Phase 3 development program on...
October 30, 2023 16:12 ET | Source: ProKidney

ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023

WINSTON-SALEM, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
September 05, 2023 06:05 ET | Source: ProKidney

ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference

WINSTON-SALEM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on...
August 10, 2023 16:10 ET | Source: ProKidney

ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights

WINSTON-SALEM, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on...
July 18, 2023 06:05 ET | Source: ProKidney

ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC

WINSTON-SALEM, N.C., July 18, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on...
July 17, 2023 06:05 ET | Source: ProKidney

ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization

- Brings more than 20 years of academic and industry experience with extensive expertise in kidney disease - WINSTON-SALEM, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)...